On Tuesday, Healthcare Realty Trust (NYSE:HR) experienced a revision in its financial outlook as Citi adjusted the company's stock price target. The new target has been set at $13.00, a decrease from the previous $17.50, while the firm maintained a Neutral rating for the stock.
This adjustment comes in the wake of the company's fourth-quarter results, which prompted a reevaluation of the real estate investment trust's operational and transactional projections.
The reassessment by Citi follows the release of Healthcare Realty Trust's fourth-quarter earnings. The firm's revised model for the company now incorporates updated assumptions about its operations and transactions.
Consequently, there has been a downward revision in the core Funds From Operations (FFO) per share estimates for the next two years. For 2024, the core FFO per share estimate has been reduced to $1.57 from the previous forecast of $1.60. Similarly, the 2025 estimate has seen a decrease to $1.62 from the earlier projection of $1.64.
The change in price target reflects the updated expectations for Healthcare Realty Trust's financial performance. Citi's analysis indicates a recalibration of the company's value based on the newly anticipated core FFO figures. The reduction in the price target to $13.00 from $17.50 aligns with the revised earnings estimates for the upcoming years.
Healthcare Realty Trust, which specializes in owning, managing, and developing properties that serve the healthcare industry, has not made any public comments regarding the new price target or the analyst's remarks. The company's stock performance and investor sentiment may be influenced by such financial assessments from major analytical firms like Citi.
Investors and market watchers will likely monitor Healthcare Realty Trust's future financial reports and operational developments to gauge the accuracy of Citi's revised estimates and the impact on the company's market valuation. The revised stock price target is now a point of reference for the investment community as they assess the company's stock potential moving forward.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.